Semaglutide (Ozempic/Wegovy)
The GLP-1 receptor agonist initiated at 0.25 mg weekly for type 2 diabetes and weight loss is semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity.
Dosing and Titration
Semaglutide is formulated as a once-weekly subcutaneous injection with a half-life of 183 hours 1. The medication starts at 0.25 mg weekly and is titrated monthly as tolerated up to a maximum dose of 2.4 mg weekly for obesity treatment 1. For type 2 diabetes, FDA-approved doses are 0.5 mg, 1 mg, and 2 mg weekly 1.
The slow titration schedule is critical:
- Week 1-4: 0.25 mg weekly
- Week 5-8: 0.5 mg weekly
- Week 9-12: 1.0 mg weekly
- Week 13-16: 1.7 mg weekly
- Week 17+: 2.4 mg weekly (maximum dose for obesity)
This gradual escalation mitigates gastrointestinal side effects, which are dose-dependent 2, 3.
Efficacy for Weight Loss and Diabetes
Semaglutide demonstrates superior efficacy compared to other GLP-1 receptor agonists for both weight reduction and glycemic control 4, 5.
Weight Loss Outcomes
- STEP 1 trial: 16.9% mean weight reduction at 68 weeks with 2.4 mg weekly (vs. 2.4% with placebo) 1
- STEP 5 trial: 16.7% weight reduction maintained at 2 years 1
- 68% of participants in STEP 1 lost ≥5% body weight 5
- Mean weight loss of 14.9% in non-diabetic patients with obesity 2
Glycemic Control
- A1C reduction of 1.1-2.2% depending on baseline and dose 1, 6
- SUSTAIN-FORTE trial: 2.2% A1C reduction with 2.0 mg vs. 1.9% with 1.0 mg 1
- Superior glucose-lowering compared to sitagliptin, insulin glargine, exenatide ER, and dulaglutide 6
Cardiovascular and Mortality Benefits
Semaglutide 2.4 mg weekly is FDA-approved for secondary cardiovascular risk reduction based on the SELECT trial 1.
- 20% reduction in 3-point MACE (nonfatal MI, nonfatal stroke, CV death) over mean 34 months exposure 1
- SUSTAIN-6 trial: Reduced composite MACE outcome driven by reduction in nonfatal stroke 1
- Benefits demonstrated in patients with established CVD and obesity, both with and without type 2 diabetes 1, 2
Additional Clinical Benefits
Beyond weight and glucose control, semaglutide provides:
- Prevention of progression from prediabetes to type 2 diabetes 1
- Prevention of decline in renal function 1
- Improvement in heart failure with preserved ejection fraction (HFpEF) 1
- Improvement in MASH (metabolic dysfunction-associated steatohepatitis) histology and fibrosis 1
Side Effects and Management
Gastrointestinal adverse events are the most common side effects 4, 2, 5:
- Nausea (most common, ~25% of patients) 4
- Vomiting and diarrhea (up to 10% each) 4
- Constipation, dyspepsia, abdominal distension 3
Mitigation Strategies
- Slow dose titration is essential 7, 2
- Eat smaller meals and stop when feeling full 4
- Drink plenty of water and increase dietary fiber 4
- Avoid high-fat or spicy foods 4
- Moderate alcohol and carbonated drinks 4
Serious Adverse Events to Monitor
- Acute pancreatitis: Discontinue if suspected and do not restart if confirmed 7, 3
- Gallbladder disorders (cholelithiasis, acute cholecystitis) 8, 3
- Diabetic retinopathy complications (reported with semaglutide, though causality unclear) 7
- Delayed gastric emptying: May increase aspiration risk during anesthesia 2, 8
- Hypoglycemia when combined with insulin or sulfonylureas 7, 3
Contraindications
Absolute contraindications 7, 3:
- Personal or family history of medullary thyroid cancer
- Personal or family history of multiple endocrine neoplasia type 2 (MEN2)
- Pregnancy or breastfeeding
- History of serious hypersensitivity reaction to semaglutide
Clinical Considerations
Renal dosing: No dosage adjustment required for eGFR ≥30 mL/min/1.73 m² 7. Use caution with eGFR 15-29 and monitor renal function 7.
Treatment duration: Long-term use is necessary as weight regain occurs with discontinuation. STEP 4 showed 6.9% weight regain after stopping treatment 5. Any prescription should include a plan to mitigate adverse effects of treatment termination 9.
Response assessment: If patient has not lost at least 4% of body weight after 16 weeks, consider discontinuation 3.
Combination with lifestyle modification: Semaglutide must be used in conjunction with reduced-calorie diet and increased physical activity for optimal efficacy 5, 9.